<DOC>
	<DOCNO>NCT01621100</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness tolerability Once-Daily OROS ( `` Osmotic Release Oral System '' [ control release oral medication delivery system form tablet ] ) hydromorphone cancer pain treatment Korean cancer patient .</brief_summary>
	<brief_title>Study Evaluate Effectiveness Tolerability OROS Hydromorphone Cancer Pain Treatment Korean Patients</brief_title>
	<detailed_description>This prospective ( expect happen ) , open-label ( type clinical study researcher participant know treatment administer ) , multicenter ( conduct multiple center ) , single-arm ( one group ) , study evaluate effectiveness tolerability ( capable tolerate ) Once-Daily OROS hydromorphone cancer pain treatment . This 14-week study consist 2-week efficacy evaluation period ( 1st evaluation Day 1 2nd evaluation Days 15Â±2 ) 12-week extension phase . 99 patient receive Once-Daily OROS hydromorphone 2 week .After 2 week , patient continuous cancer pain investigator deem necessary administer medicine study medication patient may participate voluntarily 12 week extension phase . At extension phase , continuous-type strong opioid analgesic ( painkiller ) may administer time adjustment cancer pain base discretion investigator .</detailed_description>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Cancer pain require opioid analgesic Average pain intensity measure baseline ( patient 's medical status treatment research do ) past 24 hour Numeric Rating Scale ( NRS ) 4 Never take continuoustype strong opioid analgesic Must postmenopausal premenopausal , must use acceptable method birth control Acute digestion related disease , dysphagia ( difficulty swallow ) , vomit , enterokinesia ( movement intestine ) , intestinal obstruction , acute intestinal stricture ( narrow passageway ) Expected undergo radioactive treatment ( radiation therapy ) Day 1 Day 15 study Being administer monoamine oxidase inhibitor ( eg , moclobemide , selegiline , toloxatone , etc ) within 2 week administration thereof</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Cancer pain</keyword>
	<keyword>OROS</keyword>
	<keyword>Osmotic release oral system</keyword>
	<keyword>Hydromorphone</keyword>
	<keyword>Painkiller</keyword>
	<keyword>Opioid analgesic</keyword>
	<keyword>Korean patient</keyword>
</DOC>